Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

GC-072: A Novel Therapeutic Candidate for Oral Treatment of Melioidosis and Infections Caused by Select Biothreat Pathogens.

Shearer JD, Saylor ML, Butler CM, Treston AM, Heine HS, Chirakul S, Schweizer HP, Louie A, Drusano GL, Zumbrun SD, Warfield KL.

Antimicrob Agents Chemother. 2019 Sep 23. pii: AAC.00834-19. doi: 10.1128/AAC.00834-19. [Epub ahead of print]

2.

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo.

Warfield KL, Warren TK, Qiu X, Wells J, Mire CE, Geisbert JB, Stuthman KS, Garza NL, Van Tongeren SA, Shurtleff AC, Agans KN, Wong G, Callahan MV, Geisbert TW, Klose B, Ramstedt U, Treston AM.

Antiviral Res. 2017 Feb;138:22-31. doi: 10.1016/j.antiviral.2016.11.019. Epub 2016 Nov 28.

PMID:
27908828
3.

Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4.

Warfield KL, Plummer EM, Sayce AC, Alonzi DS, Tang W, Tyrrell BE, Hill ML, Caputo AT, Killingbeck SS, Beatty PR, Harris E, Iwaki R, Kinami K, Ide D, Kiappes JL, Kato A, Buck MD, King K, Eddy W, Khaliq M, Sampath A, Treston AM, Dwek RA, Enterlein SG, Miller JL, Zitzmann N, Ramstedt U, Shresta S.

Antiviral Res. 2016 May;129:93-98. doi: 10.1016/j.antiviral.2016.03.001. Epub 2016 Mar 3.

4.

A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer.

Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR.

Invest New Drugs. 2011 Apr;29(2):340-6. doi: 10.1007/s10637-009-9383-9. Epub 2010 Jan 19.

5.

Synthesis and antitumor activities of 3-modified 2-methoxyestradiol analogs.

Suwandi LS, Agoston GE, Shah JH, Hanson AD, Zhan XH, Lavallee TM, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 15;19(22):6459-62. doi: 10.1016/j.bmcl.2009.09.009. Epub 2009 Sep 9.

PMID:
19782568
6.

Synthesis, antiproliferative, and pharmacokinetic properties of 3- and 17-double-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Suwandi L, Hanson AD, Zhan X, LaVallee TM, Pribluda V, Treston AM.

Bioorg Med Chem Lett. 2009 Nov 1;19(21):6241-4. doi: 10.1016/j.bmcl.2009.08.020. Epub 2009 Aug 8.

PMID:
19782564
7.

Synthesis of 2- and 17-substituted estrone analogs and their antiproliferative structure-activity relationships compared to 2-methoxyestradiol.

Shah JH, Agoston GE, Suwandi L, Hunsucker K, Pribluda V, Zhan XH, Swartz GM, LaVallee TM, Treston AM.

Bioorg Med Chem. 2009 Oct 15;17(20):7344-52. doi: 10.1016/j.bmc.2009.08.038. Epub 2009 Aug 21.

PMID:
19762246
8.

Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198.

LaVallee TM, Burke PA, Swartz GM, Hamel E, Agoston GE, Shah J, Suwandi L, Hanson AD, Fogler WE, Sidor CF, Treston AM.

Mol Cancer Ther. 2008 Jun;7(6):1472-82. doi: 10.1158/1535-7163.MCT-08-0107.

9.

Synthesis and in vivo antitumor evaluation of 2-methoxyestradiol 3-phosphate, 17-phosphate, and 3,17-diphosphate.

Edsall AB, Agoston GE, Treston AM, Plum SM, McClanahan RH, Lu TS, Song W, Cushman M.

J Med Chem. 2007 Dec 27;50(26):6700-5. Epub 2007 Dec 6.

PMID:
18052315
10.

Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol.

Agoston GE, Shah JH, Lavallee TM, Zhan X, Pribluda VS, Treston AM.

Bioorg Med Chem. 2007 Dec 15;15(24):7524-37. Epub 2007 Sep 14.

PMID:
17910916
11.

Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer.

James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, Miller KD.

Invest New Drugs. 2007 Feb;25(1):41-8. Epub 2006 Sep 13.

PMID:
16969706
12.

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.

Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ.

Cancer Res. 2002 Apr 15;62(8):2300-5.

13.

Peptidylglycine alpha-amidating monooxygenase- and proadrenomedullin-derived peptide-associated neuroendocrine differentiation are induced by androgen deprivation in the neoplastic prostate.

Jiménez N, Jongsma J, Calvo A, van der Kwast TH, Treston AM, Cuttitta F, Schröder FH, Montuenga LM, van Steenbrugge GJ.

Int J Cancer. 2001 Oct 1;94(1):28-34.

14.

Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer.

Zhou J, Allred DC, Avis I, Martínez A, Vos MD, Smith L, Treston AM, Mulshine JL.

Breast Cancer Res Treat. 2001 Apr;66(3):217-24.

PMID:
11510693
15.

Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis.

Shah JH, Swartz GM, Papathanassiu AE, Treston AM, Fogler WE, Madsen JW, Green SJ.

J Med Chem. 1999 Aug 12;42(16):3014-7. No abstract available.

PMID:
10447943
16.

Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors.

Iwai N, Martínez A, Miller MJ, Vos M, Mulshine JL, Treston AM.

Lung Cancer. 1999 Mar;23(3):209-22.

PMID:
10413197
17.
18.

Immunocytochemical mapping of the amidating enzyme PAM in the developing and adult mouse lung.

Guembe L, Villaro AC, Treston AM.

J Histochem Cytochem. 1999 May;47(5):623-36.

PMID:
10219055
19.

Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development.

Montuenga LM, Zhou J, Avis I, Vos M, Martinez A, Cuttitta F, Treston AM, Sunday M, Mulshine JL.

Am J Respir Cell Mol Biol. 1998 Oct;19(4):554-62.

PMID:
9761751
20.

Peptide-amidating enzymes are expressed in the stellate epithelial cells of the thymic medulla.

Martínez A, Farr A, Vos MD, Cuttitta F, Treston AM.

J Histochem Cytochem. 1998 May;46(5):661-8.

PMID:
9562574
21.

Recent molecular advances in the approach to early lung cancer detection and intervention.

Mulshine JL, Scott F, Zhou J, Avis I, Vos M, Treston AM.

Environ Health Perspect. 1997 Jun;105 Suppl 4:935-9. Review.

22.

New approaches to the integrated management of early lung cancer.

Mulshine JL, Zhou J, Treston AM, Szabo E, Tockman MS, Cuttitta F.

Hematol Oncol Clin North Am. 1997 Apr;11(2):235-52. Review.

PMID:
9137968
23.

Where does amidation take place?

Martinez A, Treston AM.

Mol Cell Endocrinol. 1996 Oct 30;123(2):113-7. Review. No abstract available.

PMID:
8961247
24.

Expression of peptidyl-glycine alpha-amidating mono-oxygenase (PAM) enzymes in morphological abnormalities adjacent to pulmonary tumors.

Martínez A, Treston AM, Saldise L, Montuenga LM, Linnoila RI.

Am J Pathol. 1996 Aug;149(2):707-16.

25.

Peptide amidating activity in human bronchoalveolar lavage fluid.

Scott FM, Treston AM, Shaw GL, Avis I, Sorenson J, Kelly K, Dempsey EC, Cantor AB, Tockman M, Mulshine JL.

Lung Cancer. 1996 Jun;14(2-3):239-51.

PMID:
8794407
26.

Insulin-like growth factor expression in human cancer cell lines.

Quinn KA, Treston AM, Unsworth EJ, Miller MJ, Vos M, Grimley C, Battey J, Mulshine JL, Cuttitta F.

J Biol Chem. 1996 May 10;271(19):11477-83.

28.

Development of Molecular Approaches to Early Lung Cancer Detection.

Mulshine JL, Scott F, Zhou J, Avis I I, Vos M, Miller MJ, Szabo E, Martinez A, Treston AM, Cuttitta F, Tockman M.

Semin Radiat Oncol. 1996 Apr;6(2):72-75.

PMID:
10717164
29.

Growth control of lung cancer by interruption of 5-lipoxygenase-mediated growth factor signaling.

Avis IM, Jett M, Boyle T, Vos MD, Moody T, Treston AM, Martínez A, Mulshine JL.

J Clin Invest. 1996 Feb 1;97(3):806-13.

30.

Expression in human lung cancer cell lines of genes of prohormone processing and the neuroendocrine phenotype.

Vos MD, Scott FM, Iwai N, Treston AM.

J Cell Biochem Suppl. 1996;24:257-68.

PMID:
8806108
31.
32.

Isolation and functional expression of human pancreatic peptidylglycine alpha-amidating monooxygenase.

Tateishi K, Arakawa F, Misumi Y, Treston AM, Vos M, Matsuoka Y.

Biochem Biophys Res Commun. 1994 Nov 30;205(1):282-90. Erratum in: Biochem Biophys Res Commun 1995 Jan 17;206(2):805.

PMID:
7999037
33.

Peptidylglycine alpha-amidating monooxygenase (PAM) immunoreactivity and messenger RNA in human pituitary and increased expression in pituitary tumours.

Steel JH, Martínez A, Springall DR, Treston AM, Cuttitta F, Polak JM.

Cell Tissue Res. 1994 Apr;276(1):197-207.

PMID:
8187161
34.

Biochemical characterization of peptide alpha-amidation enzyme activities of human neuroendocrine lung cancer cell lines.

Treston AM, Scott FM, Vos M, Iwai N, Mains RE, Eipper BA, Cuttitta F, Mulshine JL.

Cell Growth Differ. 1993 Nov;4(11):911-20.

35.

Scientific basis for cancer prevention. Intermediate cancer markers.

Mulshine JL, Jett M, Cuttitta F, Treston AM, Quinn K, Scott F, Iwai N, Avis I, Linnoila RI, Shaw GL.

Cancer. 1993 Aug 1;72(3 Suppl):978-83. Review.

PMID:
8334673
36.

Prospective trial evaluating immunocytochemical-based sputum techniques for early lung cancer detection: assays for promotion factors in the bronchial lavage.

Scott F, Cuttitta F, Treston AM, Avis I, Gupta P, Ruckdeschel J, Kelly K, Piantadosi S, Tockman M, Mulshine J.

J Cell Biochem Suppl. 1993;17F:175-83.

PMID:
8412189
37.

Initiators and promoters of lung cancer.

Mulshine JL, Treston AM, Brown PH, Birrer MJ, Shaw GL.

Chest. 1993 Jan;103(1 Suppl):4S-11S. Review.

PMID:
8380133
38.

Effect of gastrin-releasing peptide on the pancreatic tumor cell line (Capan).

Avis I, Jett M, Kasprzyk PG, Cuttitta F, Treston AM, Maneckjee R, Mulshine JL.

Mol Carcinog. 1993;8(4):214-20.

PMID:
8280369
39.

A mitogenic peptide amide encoded within the E peptide domain of the insulin-like growth factor IB prohormone.

Siegfried JM, Kasprzyk PG, Treston AM, Mulshine JL, Quinn KA, Cuttitta F.

Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8107-11.

40.
41.

Candidate biomarkers for application as intermediate end points of lung carcinogenesis.

Mulshine JL, Linnoila RI, Treston AM, Scott FM, Quinn K, Avis I, Shaw GL, Jensen SM, Brown P, Birrer MJ, et al.

J Cell Biochem Suppl. 1992;16G:183-6. Review.

PMID:
1469899
42.

Growth factors and other targets for rational application as intervention agents.

Mulshine JL, Birrer M, Treston AM, Scott F, Quinn K, Avis I, Cuttitta F.

Adv Exp Med Biol. 1992;320:81-8. Review. No abstract available.

PMID:
1442286
43.

Control of tumor cell biology through regulation of peptide hormone processing.

Treston AM, Mulshine JL, Cuttitta F.

J Natl Cancer Inst Monogr. 1992;(13):169-75. Review.

PMID:
1389690
44.

Alpha-amidation of peptide hormones in lung cancer.

Quinn KA, Treston AM, Scott FM, Kasprzyk PG, Avis I, Siegfried JM, Mulshine JL, Cuttitta F.

Cancer Cells. 1991 Dec;3(12):504-10. Review.

PMID:
1668141
45.

Preclinical evaluation of an anti-autocrine growth factor monoclonal antibody for treatment of patients with small-cell lung cancer.

Avis IL, Kovacs TO, Kasprzyk PG, Treston AM, Bartholomew R, Walsh JH, Cuttitta F, Mulshine JL.

J Natl Cancer Inst. 1991 Oct 16;83(20):1470-6.

PMID:
1656058
46.

Lung cancer: rational strategies for early detection and intervention.

Mulshine JL, Treston AM, Scott FM, Avis I, Boland C, Phelps R, Kasprzyk PG, Nakanishi Y, Cuttitta F.

Oncology (Williston Park). 1991 May;5(5):25-32; discussion 32-3, 37.

PMID:
1832003
48.

Autocrine growth factors as therapeutic targets in lung cancer.

Mulshine JL, Treston AM, Natale RB, Kasprzyk PG, Avis I, Nakanishi Y, Cuttitta F.

Chest. 1989 Jul;96(1 Suppl):31S-34S. Review. No abstract available.

PMID:
2661168
49.

Peptide structure. Beyond transcriptional events.

Treston AM, Mulshine JL.

Nature. 1989 Feb 2;337(6206):406. No abstract available.

PMID:
2644539
50.

Autocrine growth factors and lung cancer.

Mulshine JL, Natale RB, Avis I, Treston AM, Kasprzyk PG, Nakanishi Y, Sausville EA, Trepel JB, Cuttitta F.

Cancer Treat Res. 1989;45:107-22. Review. No abstract available.

PMID:
2577167

Supplemental Content

Loading ...
Support Center